The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
Executive Summary
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
You may also be interested in...
Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill
However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.
Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill
However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.
Medicare Director: ‘Bona-Fide’ Generic Marketing Likely Product-Specific For IRA
CMS won’t put a number on ‘bona fide” generic and biosimilar competition. Medicare's head also discussed how it will ensure rebates don’t disadvantage drugs with government-negotiated prices.